Publication & Citation Trends
Publications
0 total
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma OA
Cited by 152
Semantic Scholar
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase OA
Cited by 23
Semantic Scholar
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers OA
Cited by 368
Semantic Scholar
Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies
Cited by 15
Semantic Scholar
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. OA
Cited by 377
Semantic Scholar
Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. OA
Cited by 64
Semantic Scholar
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model OA
Cited by 12
Semantic Scholar
Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1* OA
Cited by 80
Semantic Scholar
Structural Biology of Mutant IDH2 Inhibition OA
Cited by 0
Semantic Scholar
Abstract PL02-04: IDH mutations and tumorigenicity.
Cited by 1
Semantic Scholar
Research Topics
Biochemical and Molecular Research
(14)
Cancer, Hypoxia, and Metabolism
(13)
Acute Myeloid Leukemia Research
(10)
Adolescent and Pediatric Healthcare
(9)
Neonatal Health and Biochemistry
(8)
Affiliations
Goethe University Frankfurt
Florida International University
University of Würzburg
Agios Pharmaceuticals (United States)
Magnetic Resonance Imaging Institute for Biomedical Research